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Purpose: Within the spectrum of the Ehlers-Danlos syndromes
(EDS), vascular complications are usually associated with the
vascular subtype of EDS. Vascular complications are also observed
in other EDS subtypes, but the reports are anecdotal and the
information is dispersed. To better document the nature of vascular
complications among “nonvascular” EDS subtypes, we performed
a systematic review.
Methods: We queried three databases for English-language
studies from inception until May 2017, documenting both
phenotypes and genotypes of patients with nonvascular EDS
subtypes. The outcome included the number and nature of vascular
complications.
Results: A total of 112 papers were included and data were
collected from 467 patients, of whom 77 presented with a vascular
phenotype. Severe complications included mainly hematomas
(53%), frequently reported in musculocontractural and classical-
like EDS; intracranial hemorrhages (18%), with a high risk in
dermatosparaxis EDS; and arterial dissections (16%), frequently
reported in kyphoscoliotic and classical EDS. Other, more minor,
vascular complications were reported in cardiac-valvular, arthro-
chalasia, spondylodysplastic, and periodontal EDS.
Conclusion: Potentially life-threatening vascular complications are
a rare but important finding in several nonvascular EDS sub-
types, highlighting a need for more systematic documentation. This
review will help familiarize clinicians with the spectrum of vascular
complications in EDS and guide follow-up and management.
Genet Med advance online publication 5 October 2017
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INTRODUCTION
The Ehlers-Danlos syndrome (EDS) is an umbrella term for a
group of clinically and genetically heterogeneous connective
tissue disorders. Over the past two decades the Villefranche
Nosology has been the standard for classifying EDS. It
recognized six subtypes, most of which were caused by defects
in the primary structure of collagen or collagen-modifying
enzymes.1 Recent discoveries have, however, expanded the
pathogenic spectrum to include EDS variants that are caused
by defects in both noncollagenous extracellular matrix
proteins and intracellular processes.2–10 This has led to an
EDS reclassification: a task that was recently accomplished by
an international EDS consortium.11
Skin hyperextensibility and joint hypermobility are the
clinical hallmarks of EDS, but more variable signs of soft
connective tissue fragility are helpful in discriminating
between the different types. Historically, arterial aneurysm
and dissection have been synonymous with the vascular type
of EDS (vEDS). This type of EDS is characterized by the
presence of a thin, translucent skin, which bruises very
easily, and joint hypermobility, which is often confined to
the small joints. The clinical picture is, however, dominated
by a remarkable vascular fragility that leads to spontaneous
rupture of blood vessel walls, often without preceding vascular
dilatation or aneurysm formation. Other life-threatening
complications include rupture of the gastrointestinal (GI)
tract, gravid uterus, or other internal organs, such as liver or
spleen.12 The calculated median survival for vEDS patients is
48 years, with most deaths resulting from arterial rupture.13
Complications are rare in childhood, but 25% will have a first
complication by the age of 20 years, and more than 80% will
have had at least one complication by the age of 40 years.
Therapeutic interventions are limited to symptomatic
measures.14 Hitherto, the only evidence-based treatment
strategy has been the administration of celiprolol, a
cardioselective β-blocker with β2 agonist vasodilatory proper-
ties, which has been reported to reduce heart rate and
pulsatile pressures in essential hypertension and could
therefore decrease the continuous and pulsatile mechanical
stress on collagen fibers within the arterial wall.15,16 vEDS is
caused by heterozygous mutations in the type III procollagen-
encoding gene COL3A1.17 Genotype–phenotype correlations
have been extensively investigated. Substitution of triple
helical glycine residues and splice donor site mutations,
leading to exon skipping, are generally associated with a
shorter life expectancy, whereas mutations leading to COL3A1
haploinsufficiency are usually associated with a milder
phenotype, a delay in the onset of complications, and a
longer life expectancy.18,19
Vascular complications, including arterial aneurysms and
ruptures, subcutaneous hematomas, gum bleeding, and
prolonged perioperative and menstrual bleeding, have also
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been described in other, “nonvascular” subtypes of EDS.20,21
Most of these reports are anecdotal, and the occurrence of
such complications in the different EDS subtypes is not well
documented. In view of the vast clinical and genetic
heterogeneity of EDS, it may therefore be difficult for
clinicians to predict, for a specific EDS patient, whether
vascular complications should be taken into account, and how
patients should be followed.
We reviewed the medical literature on EDS in a systematic
manner to better document the nature of vascular complica-
tions in patients with a nonvascular EDS diagnosis confirmed
via molecular testing. This review will help familiarize
clinicians with the spectrum of vascular complications in
nonvascular EDS subtypes as well as guide follow-up and
management.
MATERIALS AND METHODS
Study design
This systematic review was designed and carried out in
accordance with the guidelines of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses statement
for reporting systematic reviews.22
Search strategy
The aim of this study was to collect all available data on
vascular complications in the nonvascular EDS subtypes
described in the updated EDS classification (Table 1). We
queried the PubMed and Web of Science databases, taking
into account the different notations for the EDS subtypes
(e.g., classic versus classical). For classical EDS (COL5A1/2),
for example, the following keywords were used: Ehlers-Danlos
syndrome, classic*, COL5A1, COL5A2, Ehlers-Danlos syn-
drome type I, Ehlers-Danlos syndrome type II. All keywords
for each EDS subtype are outlined in Table 1. Based on these
keywords, search strings to query the respected databases for,
for example, classical EDS (COL5A1/2) were constructed as
follows: (“Ehlers-Danlos syndrome”[Title/Abstract] AND
(classic*[Title/Abstract] OR COL5A1[Title/Abstract] OR
COL5A2[Title/Abstract])) OR “Ehlers-Danlos syndrome
type I”[Title/Abstract] OR “Ehlers-Danlos syndrome type
II”[Title/Abstract]. To exclude nonrelevant references, queries
were restricted to “title” and “abstract” in PubMed and
“topic” in Web of Science. All search strings are outlined in
Supplementary Table S1 online. The Leiden Open Variation
Database (http://www.lovd.nl/3.0/home) was queried for
additional references. All references published from inception
Table 1 Overview of all nonvascular subtypes of the Eherls-Danlos syndrome included in this systematic review
EDS type IP Gene Protein Keywords
Classical (cEDS) AD COL5A1/2
COL1A1
Type V collagen
Type I collagen (p.(Arg312Cys))
Ehlers-Danlos syndrome, classic*, COL5A1, COL5A2,
Ehlers-Danlos syndrome type I, Ehlers-Danlos syndrome
type II
Ehlers-Danlos syndrome, COL1A1
Classical-like (clEDS) AR TNXB Tenascin X Ehlers-Danlos syndrome, TNXB, tenascin-x
Cardiac-valvular (cvEDS) AR COL1A2 Type I collagen (total absence
of α2 chain)
Ehlers-Danlos syndrome, COL1A2
Arthrochalasia (aEDS) AD COL1A1/2 Type I collagen (N-propeptide
processing)
Ehlers-Danlos syndrome, arthrochalasia, Ehlers-Danlos
syndrome type VIIA, Ehlers-Danlos syndrome type VIIB
Dermatosparaxis (dEDS) AR ADAMTS2 ADAMTS2 Ehlers-Danlos syndrome, dermatospara*, ADAMTS2,
Ehlers-Danlos syndrome type VIIC
Kyphoscoliotic (kEDS) AR PLOD1
FKBP14
LH1
FKBP22
Ehlers-Danlos syndrome, kyphoscolio*, PLOD1,
Ehlers-Danlos syndrome type VIA
Ehlers-Danlos syndrome, FKBP14
Brittle cornea syndrome
(BCS)
AR ZNF469
PRDM5
ZNF469
PRDM5
Brittle cornea syndrome, ZNF469, PRDM5
Spondylodysplastic
(spEDS)
AR B4GALT7
B3GALT6
SLC39A13
β4GalT7
β3GalT6
ZIP13
Ehlers-Danlos syndrome, progeroid, B4GALT7
Ehlers-Danlos syndrome, progeroid, B3GALT6 Ehlers-Danlos
syndrome, spondylocheirodysplas*, SLC39A13
Musculocontractural
(msEDS)
AR CHST14
DSE
D4ST1
DSE
Ehlers-Danlos syndrome, musculocontractural, CHST14, DSE,
Ehlers-Danlos syndrome type VIB, adducted thumb-clubfoot
syndrome, Ehlers-Danlos syndrome Kosho type,
D4ST1-deficient Ehlers-Danlos syndrome
Myopathic (mEDS) AR/AD COL12A1 Type XII collagen Ehlers-Danlos syndrome, COL12A1
Periodontal (pEDS) AD C1R/S C1r and C1s Ehlers-Danlos syndrome, periodontal, C1R, C1S
AD, autosomal dominant; AR, autosomal recessive; EDS, Ehlers-Danlos syndrome; IP, inheritance pattern.
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until 31 May, 2017 were eligible for inclusion in this review. A
bibliography was created using EndNote X7 (Thomson
Reuters, New York, NY).
Screening process and eligibility criteria
Primary literature screening was performed by two investi-
gators (S.D. and T.V.D.), independently, according to the
following inclusion criteria: (i) population: nonvascular
subtypes of EDS, (ii) language: English, (iii) papers: no short
conference proceedings or meeting abstracts, and (iv)
availability of the full text. Next, eligibility for inclusion in
the review after full-text screening of the remaining papers
was further assessed using the following criteria: descriptions
of both (i) the patient’s phenotype and (ii) the pathogenic
genetic defect. Patients for whom only linkage to a gene or a
biochemical diagnosis was demonstrated were excluded.
Hypermobile EDS was also not included, since its genetic
etiology remains unknown and because—prior to the updated
2017 classification on EDS11—its definition covered a broad
clinical spectrum, with variable signs of connective tissue
fragility that closely overlapped with joint hypermobility
syndrome. The following types of studies were considered:
clinical trials, case-control studies, cross-sectional studies,
cohort studies, case series, and case reports published in peer-
reviewed scientific journals. Excluded were cell culture
laboratory studies, animal studies, and reviews. Titles and
abstracts were checked with regard to the predefined
eligibility criteria. Abstracts with unclear methodology were
included in full-text assessment to avoid exclusion of
potentially relevant papers.
Quality assessment
Quality assessment tools for case series, case-control,
cross-sectional, and cohort studies are available from the
National Heart, Blood, and Lung Institute (Bethesda, MD)
(https://www.nhlbi.nih.gov/). Quality assessment tools for
case reports are available from the Joanna Briggs Institute
(Adelaide, Australia) (http://joannabriggs.org/). Each study
was classified into one of the following groups: (i) good if all
quality criteria were judged as “present,” (ii) fair if one or
more key domains were “unclear,” or (iii) poor if one or more
key domains were “absent” (Supplementary Table S2).
Data extraction and aggregation
Data extraction and aggregation were performed by a single
investigator (S.D.). Uncertainties were resolved through
discussion with the principal investigator (F.M.). The
following data, if available, were extracted from the included
references: (i) study characteristics (authors and year of
publication), (ii) patient attributes (patient and family
identifiers, age at time of referral or vascular complication,
and relevant comorbidities), (iii) vascular features (type and
location of vascular complication, recurrence, management,
and cause of death), and (iv) mutation. If a patient or family
was described more than once, the most informative reference
was used for data collection. The spectrum of vascular
complications was further categorized into (i) hematomas,
(ii) intracranial hemorrhages, (iii) arterial dissections, (iv)
arterial aneurysms, (v) GI bleedings, (vi) perioperative
hemorrhages, and (vii) sporadic vascular complications. The
data collection on hematomas included only those that
occurred spontaneously or from minor trauma or were
described as severe in nature (e.g., “large,” “massive,”
“repeated,” “profuse”). Easy bruising was not included in this
study for many reasons. It is often described in a non-
descriptive manner, and as a symptom it is often overreported
by both patients and caregivers. We therefore felt that
including easy bruising would lead to an overrepresentation
of vascular complications in nonvascular EDS. The primary
outcome of these data-processing procedures was the
derivation of the total number of nonvascular EDS patients,
along with the number of patients reported with, respectively,
none, one, or more than one vascular complication. The
secondary outcome included the number, type, and location
of reported vascular complications.
RESULTS
Search results and study characteristics
A flow diagram of the search selection process is depicted in
Figure 1. Our search strategy identified 809 unique papers,
547 of which were excluded after primary screening based on
title and abstract. From the remaining 262 papers selected for
full-text screening, 112 papers were found to meet the
predefined inclusion criteria (Figure 1). All included papers
are listed in Supplementary Table S2 and a brief overview of
all included studies and patients is presented in Table 2. The
types of studies reported by these papers included mainly case
reports (n = 51) and series (n = 59), a cross-sectional study
(n = 1), and a cohort study (n = 1). There was a quality
assessment of the included papers, of which 38 were classified
as good, 43 as fair, and 31 as poor. None of them were
rejected based on assessed quality alone, so that a large
population could be obtained, based on which it is possible
to draw firm conclusions. These 112 papers report on 467
patients (197 males, 238 females, and 32 not defined) from
342 unrelated families, and include 29 papers on classical
EDS (cEDS; COL5A1/2: n = 25; COL1A1 p.(Arg312Cys):
n= 4),23–51 6 on classical-like EDS (clEDS; TNXB),52–57 three
on cardiac-valvular EDS (cvEDS; COL1A2),58–60 ten on
arthrochalasia EDS (aEDS; COL1A1/2),61–70 six on dermato-
sparaxis EDS (dEDS; ADAMTS2),71–76 22 on kyphoscoliotic
EDS (kEDS; PLOD1: n = 17, FKBP14: n = 5),4,77–97 ten on
brittle cornea syndrome (BCS; ZNF469: n = 5; PRDM5:
n= 5),2,98–106 11 on spondylodysplastic EDS (spEDS; B4GALT7:
n = 5; B3GALT6: n = 4; SLC39A13: n = 2),5,8,9,107–114 12 on
musculocontractural EDS (mcEDS; CHST14: n = 11;
DSE: n = 1),6,7,115–124 two on myopathic EDS (mEDS;
COL12A1),125,126 and one on periodontal EDS (pEDS; C1R/
S).127 One paper that fulfilled the inclusion criteria was withheld
because it contained data for a patient described more
thoroughly in another paper.128
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Nonvascular EDS with vascular complications
Seventy-seven of 467 (17%) individuals with nonvascular EDS
(age: ranging from birth to 62 years) were reported with a
total number of 100 vascular complications. Vascular
complications were, in terms of percentage, most frequently
reported in mcEDS-DSE (2/3, 67%), mcEDS-CHST14 (27/43,
63%), clEDS (10/19, 53%), cvEDS (2/5, 40%), dEDS (5/15,
33%), cEDS-COL1A1 (3/12, 25%), kEDS-FKBP14 (2/10, 20%),
kEDS-PLOD1 (8/54, 15%), spEDS-SLC39A13 (1/8, 13%),
cEDS-COL5A1/2 (12/110, 11%), aEDS (1/17, 6%), pEDS
(3/55, 5%), and spEDS-B3GALT6 (1/25, 4%) (Figure 2a). Of
these 77 individuals, 14 (18%) suffered more than one
complication, with an average of 1.3, ranging from one to
six complications per case. This, however, corresponds to
only 3% (14/467) of all individuals included in this syste-
matic review. The occurrence of multiple complications was
reported most frequently in mcEDS-CHST14 (8/43, 19%)
(Table 3). No vascular complications were recorded in
spEDS-B4GALT7, BCS and mEDS.
Mortality
Overall, death due to vascular complications was reported in
eight individuals (8/467, 2%). In cEDS-COL5A1, three adult
patients died from rupture of a large or medium-sized artery
(mean age: 35 years, range 28–43 years)25 and one 9-year old
patient died from multiorgan failure secondary to the rupture
of an aneurysm of the superior mesenteric artery.31 One
patient with cvEDS died from bleeding complications during
aortic valve replacement surgery at the age of 45 years.60
In dEDS, one patient died shortly after birth from severe
hemorrhage and shock.72 One patient with mcEDS-CHST14
died from a large intracerebral hemorrhage at the age of 59
years, and, finally, one with kEDS-PLOD1 died from an
arterial rupture at an unspecified site at an unknown age.89,116
Vascular phenotypes and management
To provide an overview of the type of vascular complications
in nonvascular EDS patients, each reported complication
(n = 100) was categorized as either (i) hematoma (53/100,
53%), (ii) intracranial hemorrhage (18/100, 18%), (iii) sponta-
neous arterial dissection (16/100, 16%), (iv) arterial aneurysm
(5/100, 5%), (v) GI bleeding (1/100, 1%), (vi) perioperative
hemorrhage (5/100 5%), or (vii) sporadic vascular complica-
tion (2/100, 2%). An overview of the vascular phenotypes is
presented in Figure 2b, and Table 3 summarizes the reported
type of complications per nonvascular EDS subtype.
Hematoma
The most frequent of all vascular complications was the
formation of hematomas (53/100, 53%), either spontaneously
(10/53, 19%) or after minor trauma (32/53, 60%), such as a
minor fall. They were reported primarily in mcEDS patients
(25/46, 54%) (DSE: 2/3, 67%; CHST14: 23/43, 53%)6,115–122
and clEDS patients (10/19, 53%),53,55–57 and, to a lesser extent, in
patients with dEDS (2/15, 13%)72,74 and cEDS-COL5A1 (3/110,
3%).34,38 Most hematomas were subcutaneous (41/53, 77%),
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Figure 1 Flow diagram presenting the search and selection process.
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but epidural, spinal, scalp, and stomach wall hematomas were
reported as well. Management was reported only in mcEDS,
where some hematomas from minor trauma required
transfusion (n = 7), surgical drainage (n = 6), and/or
admittance to the intensive care unit (n = 3). One mcEDS-
CHST14 patient presented with a spontaneous hematoma
and was treated with emergency surgical drainage and
transfusion.115
Intracranial hemorrhage
The second most frequently reported vascular complication
was intracranial hemorrhage (18/100, 18%), including 10
intracerebral, three subdural, one subarachnoid, one epidural,
and three unspecified hemorrhages. dEDS denoted a high risk
of intracerebral hemorrhage, affecting 20% of the patients
(3/15), mostly at birth.73,76 Intracranial hemorrhages were
also reported in mcEDS-CHST14 (4/43, 9%),116,118,120 kEDS-
PLOD1 (4/54, 7%),78,80,86,87 pEDS (2/55, 4%),127 spEDS
(2/61, 3%) (SLC39A13: 1/8, 13%; B3GALT6: 1/25, 4%),5,9
and cEDS-COL5A1 (1/110, 1%).25
Arterial dissection
Overall, 13 patients suffered a total of 16 arterial dissections
(16/100, 16%): eight patients with cEDS (8/122, 7%)
(COL1A1: 2/12, 17%; COL5A1: 6/110, 5%),25,27,33,49,50 seven
patients with kEDS (7/64, 11%) (PLOD1: 5/54, 9%; FKBP14:
2/10, 20%),79,80,89,95,97 and one with cvEDS (1/5, 20%).60
Dissections occurred most frequently in medium-sized or large
arteries, including the iliac, femoral, renal, celiac, hypogastric,
subclavian, superior mesenteric, brachial, and coronary arteries.
Aortic dissection was reported in one patient with cEDS-
COL5A1.25 Data about management is limited and mostly
Table 2 Overview of all studies and patients included in this systematic review
EDS subtype Study Quality Gender Age Race/ethnicity
cEDS (COL5A1/2) Case report (13),
case series (11),
cross-sectional (1)
Good (8), fair
(12), poor (5)
M (48), F (59),
ND (3)
2–67 y Caucasian, Turkish, Asian, black, white
cEDS (COL1A1) Case report (1),
case series (3)
Good (3),
fair (1)
M (6), F (6) 5–69 y Caucasian, Hispanic
clEDS (TNXB) Case report (3),
case series (3)
Good (3), fair
(2), poor (1)
M (8), F (11) 6–53 y Dutch
cvEDS (COL1A2) Case report (2),
case series (1)
Good (1),
fair (2)
M (3), F (2) 0–45 y Portuguese
aEDS (COL1A1/2) Case report (8),
case series (2)
Good (4), fair
(4), poor (2)
M (4), F (12),
ND (1)
0–32 y German, Japanese, Chinese, South African, Libyan
dEDS (ADAMTS2) Case report (2),
case series (4)
Good (2), fair
(3), poor (1)
M (9), F (6) 0–7 y Caucasian, Turkish, Pakistani, Ashkenazi
kEDS (PLOD1) Case report (10),
case series (6),
cohort (1)
Good (5), fair
(8), poor (4)
M (22), F (23),
ND (9)
0–7 y Macedonian, Serbian, Iranian, Somali, Iraqi, Egyptian,
Arab, Turkish, Albanian, Bosnian, Greek, Italian, Spanish,
French, Dutch, German, North American, Mexican-
American, white, Caucasian
kEDS (FKBP14) Case report (2),
case series (3)
Good (3),
poor (2)
M (5), F (5) 2–48 y Caucasian, Austrian, Italian, German, French, Turkish
BCS (ZNF469) Case series (5) Good (1), fair
(2), poor (2)
M (13), F (22) 0–28 y British, Indian, Pakistani, Saudi Arabian, Syrian, Yemeni,
Palestinian, Tunisian
BCS (PRDM5) Case report (3),
case series (2)
Fair (2), poor (3) M (4), F (12),
ND (4)
2–26 y Saudi Arabian, Pakistani, Yemeni, Syrian
spEDS (B4GALT7) Case report (2),
case series (3)
Good (4),
fair (1)
M (15), F (13) 0–46 y Arab, Danish
spEDS (B3GALT6) Case report (1),
case series (3)
Fair (1), poor (3) M (8), F (9),
ND (8)
0–34 y Japanese, Singaporean, Vietnamese, Italian, Canadian,
Brazilian, Iranian, South African
spEDS (SLC39A13) Case series (2) Fair (1), poor (1) M (4), F (4) 2–22 y Caucasian
mcEDS (CHST14) Case report (3),
case series (8)
Good (3),
fair (2), poor (6)
M (16), F (20),
ND (7)
0–59 y Hispanic, Pakistani, Curaçaoan, Moroccan, Miccosukee,
Afghani, Turkish, Japanese, Asian, Indian, Dutch, Austrian
mcEDS (DSE) Case report (1) Poor (1) M (1), F (2)a 2–48 y Indian, Spanish
mEDS (COL12A1) Case series (2) Good (1),
fair (1)
M (6), F (2) 1–48 y Turkish
pEDS (C1R/S) Case series (1) Fair (1) M (25), F (30) ND ND
BCS, brittle cornea syndrome; EDS, Ehlers-Danlos syndrome (for the definitions of the various subtypes of EDS, see Table 1); F, female; M, male; ND, not
defined. aReported in a case series of mcEDS (CHST14).
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anecdotal, but seven of these dissections were treated surgically
and two with endovascular techniques.25,27,49,79,95,97
Arterial aneurysm
Arterial aneurysms were reported in five patients (5/100, 5%),
including cEDS (4/122, 3%; COL5A1: 3/110, 3%; COL1A1:
1/12, 8%) and kEDS-PLOD1 (1/54, 2%).25,28,30,31,82 Large
(n = 1) and medium-sized (n = 3) arteries were affected and
aortic root dilatation was described in one cEDS patient.28
Three aneurysms were reported as having ruptured, two in
connection with cEDS-COL5A1 and one with kEDS-PLOD1;
they were managed using endovascular techniques.30,31,82 One
patient underwent surgery twice and was followed up using
regular computed tomography angiography.25
Gastrointestinal bleeding
Severe GI bleeding was reported in one cEDS-COL5A2 (1/110,
1%) patient, who suffered a perforation of the terminal ileum
at birth and was treated with an ileostomy.23 Several more
common GI problems are described below.
Perioperative hemorrhage
Perioperative hemorrhage (5/100, 5%) was reported in two
patients with mcEDS-CHST14 (2/43, 5%) during a laparo-
scopic procedure and surgery for dislocations,63,118,123 in one
patient with aEDS (1/18, 6%) who bled excessively at surgery
(unspecified),63 in one patient with pEDS (1/55, 2%) who had
a profuse bleeding after hysterectomy,127 and in one cvEDS
patient (1/5, 20%), who underwent aortic valve replacement
surgery and died from it at the age of 45 years.60
Sporadic vascular complications
One cEDS-COL5A1 patient (1/110, 1%) was reported with a
pulmonary artery hypoplasia,28 and one dEDS patient (1/15,
7%) presented with a pleural serohemorrhagic effusion of the
left lung.74
Common and aspecific vascular features
Several vascular and bleeding complications, which are
presumed to be relatively frequent in the general population,
have been reported in various EDS subtypes. Since these
vascular features are potentially aspecific, we listed them as
complementary but did not add them to the total number of
complications.
Menometrorrhagia was reported in two patients with cEDS-
COL5A1 (2/65 females, 3%)28 and postpartum hemorrhaging
was reported in one patient with aEDS (1/12 females, 8%)
after the birth of each of her children and in one clEDS (1/12
females, 8%).53,65 The severity of the latter was not described.
Minor GI bleeding was reported in two clEDS (2/18,
11%),53,57 two dEDS (2/15, 13%),71 two mcEDS-CHST14
(2/43, 5%),115 and one pEDS (1/55, 2%) patients.127 Two
dEDS patients suffered rectal prolapse with anal bleeding,71
and one clEDS patient had a gastric ulcer.53 The origin of
the bleeding was not specified in the other clEDS and the
pEDS patient.
Venous complications such as varicose veins and deep
venous thrombosis (DVT) were reported in a number of
patients. In cEDS, seven patients presented with varicose veins
(7/122, 6%; COL5A1: 4/110, 4%; COL1A1: 3/12, 25%) and
three with a DVT (3/110, 3%).28,33,42,44,48 Two patients with
a
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Figure 2 Vascular complications in nonvascular EDS. (a) The number of patients with vascular complications is presented for each nonvascular
EDS subtype in terms of percentage. The ratios relate to the total number of patients with vascular complication(s), to the total number per subtype.
(b) The number of each type of complication is presented in terms of percentage. EDS, Ehlers-Danlos syndrome (for the definitions of the various
subtypes of EDS, see Table 1); GI, gastrointestinal.
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spEDS-SLC39A13 (2/8, 25%) presented with varicose veins,5
and one patient with kEDS-PLOD1 (1/54, 2%) presented with
a DVT from compression stasis, which was treated by
fasciotomy.93 All of these patients were over the age of 40
years, except for the kEDS-PLOD1 patient, who presented
with a DVT at the age of 15 years.93
Five patients were reported with small bleedings: three of
these suffered from gum bleeding (mcEDS-CHST14: 2/43, 5%;
cEDS-COL5A1: 1/110, 1%),28,118,123 and two dEDS patients
suffered from epistaxis (2/15, 13%).71,129
DISCUSSION
Vascular complications are an important finding in non-
vascular subtypes of EDS. Overall, 77/467 (17%) of the
patients included in this study presented with relatively
severe vascular complications. In line with the clinical and
genetic heterogeneity of this group of disorders, there are
important differences in the number, severity, and type of
complications associated with the different EDS subtypes
(Table 3). Vascular complications, for example, are most
frequently reported in mcEDS (CHST14/DSE) and in clEDS
(TNXB), being present in about two thirds and half of the
patients, respectively. In contrast, to date no vascular
complications have been reported for spEDS-B4GALT7,
BCS, and mEDS.
In mcEDS and clEDS, the vascular phenotype shows a
large predominance of hematomas. In clEDS, hematomas are
mostly spontaneous and subcutaneous, whereas in mcEDS
they mostly occur after minor trauma, and also affect other
locations besides subcutaneous tissues (e.g., scalp, spine, and
buttock). Furthermore, these hematomas are different from
the commonly reported easy bruising in EDS and the large
hematomas in clEDS, because they can be severe in nature
and sometimes necessitate surgery and blood transfusion. Of
note, four mcEDS-CHST14 patients were reported to have
intracranial bleeding, of which one person died at the age of
59 years. Therefore, this appears to be a rare but important
complication of mcEDS.
cEDS, cvEDS, dEDS, and kEDS are associated with a lower,
but nonetheless important risk of vascular complications.
Moreover, in these subtypes, the majority of vascular
complications are severe and potentially life-threatening,
and include intracranial hemorrhages, arterial aneurysms,
and arterial dissections. The latter complications each account
for approximately 5–16% of all reported vascular complica-
tions in nonvascular EDS. Arterial aneurysms have been
reported in a few patients with cEDS (COL5A1/COL1A1)
and kEDS-PLOD1. Arterial dissections are most frequently
reported in kEDS-FKBP14 (20% of 10 kEDS-FKBP14
patients) and cEDS due to COL1A1 p.(Arg312Cys) (17% of
12 cEDS-COL1A1 patients), and to a lesser extent in kEDS-
PLOD1 (9% of 54 kEDS-PLOD1 patients) and cEDS-COL5A1
(5% of 110 cEDS-COL5A1 patients). One patient with cvEDS
was also reported to have an arterial dissection. As in vEDS,
these aneurysms and dissections mostly affect large and
medium-sized arteries, such as the iliac, femoral, renal, celiac,Ta
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hypogastric, subclavian, superior mesenteric, brachial, and
coronary arteries. Aortic dissection was reported in only one
patient with cEDS-COL5A1. Arterial aneurysms and dissec-
tions have not been reported for any of the other EDS
subtypes. Overall, arterial aneurysms and dissections are
significantly less frequently reported than in vEDS, where
such complications are reported in approximately 50% of
patients.18,130
In dEDS, 25% of the patients suffered from intracranial
hemorrhage, especially in the perinatal period. Intracranial
hemorrhage was also reported in a range of other subtypes,
including kEDS-PLOD1 (also in the perinatal period),
mcEDS-CHST14, pEDS, spEDS (SLC39A13 and B3GALT6),
and cEDS-COL5A1 (at ages ranging from 2 to 62 years).
Despite a relatively high occurrence of these severe vascular
complications, reported mortality was only 2% (8/467).
In addition to these severe and potentially life-threatening
problems, several other, and often minor, bleeding manifesta-
tions, such as gynecological and GI bleedings, perioperative
hemorrhage, varicose veins, DVT, gum bleeding, and epistaxis
have been reported in a variety of EDS subtypes, including
cEDS, clEDS, aEDS, dEDS, kEDS-PLOD1, spEDS-B3GALT6,
mcEDS-CHST14, and pEDS. However, it should be noted that
these bleeding manifestations are also relatively common in
the general population: e.g., the estimated incidence for
menometrorrhagia is 10–20%,131 3–10% for perioperative
hemorrhage,132 10–15% and 20–25% for varicose veins in
men and women respectively.133 As such, these manifesta-
tions were not counted toward the total number of vascular
complications, but were merely listed as complementary in
this review.
Data on treatment and treatment outcome of arterial
complications in nonvascular EDS are very limited, being
reported in only 11 of 77 (14%) patients with complications.
In the case of arterial aneurysms and dissections, these
patients underwent endovascular stenting (n = 5), classical
surgery (n = 4), or conservative treatment (n = 2). It is
difficult, based on the available data, to formulate guidelines
for the surveillance and follow-up of arterial aneurysms in
nonvascular EDS. Especially for subtypes associated with
increased risk for arterial dissections and aneurysms,
surveillance strategies based on noninvasive imaging,
such as ultrasound, magnetic resonance angiography, and
computed tomography angiography with or without venous
contrast, could be recommended, as in the care guidelines
for vEDS.134 Guidelines for cardiovascular care and surgery
for Marfan and Loeys-Dietz syndromes, including annual
cardiovascular imaging, blood pressure–lowering medi-
cation (e.g., angiotensin receptor blockers, β-blockers, or
angiotensin-converting enzyme inhibitors), and surgery
when approaching surgical thresholds for aortic root dimen-
sions or acute dissection, could also be used until EDS
subtype-specific recommendations are available.135,136 There
are no reports about the use of celiprolol, the β-blocker
that has proven to delay vascular complications in vEDS.15,16
One could argue, however, for its use in EDS subtypes with
an increased risk of arterial rupture and/or aneurysm (e.g.,
cEDS, kEDS). Another drug that has anecdotally been
reported to be useful in treating or preventing bleeding
episodes and/or hematomas in several EDS subtypes, such as
mcEDS, kEDS, and vEDS, is the procoagulant desmopressin
(DDAVP).116,137,138
The study’s inherent limitations should be taken into
account when interpreting the results. First, the systematic
and predefined search strategy aimed to identify all poten-
tially relevant studies, but the risk of selection bias is not
negligible. Second, extensive natural history studies on EDS
are rare: the data summarized here are derived mostly from
either case reports (n = 51) or case series (n = 59), which are
prone to publication and selection bias, because the cases are
mainly self-selected. Third, asymptomatic features (e.g., silent
aneurysms) are often not actively screened for such retro-
spective studies. Finally, for some subtypes, such as dEDS,
kEDS-FKBP14, spEDS-B4GALT7, mcEDS-DSE, and mEDS,
very few patients have been reported to date. As such, it is
likely that the current review is only a mere approxi-
mation of the occurrence and spectrum of vascular complica-
tions in nonvascular EDS.
In conclusion, vascular complications are important and
sometimes severe in some nonvascular EDS subtypes.
They are found mainly in mcEDS, clEDS, dEDS, kEDS, and
cEDS. Hematomas are most frequently reported (53%) and
predominate mcEDS and clEDS. Serious, potentially life-
threatening complications such as intracranial hemorrhage,
arterial aneurysms, and dissections of large and medium-sized
arteries, account for approximately 18, 5 and 16% of vascular
complications, respectively, and are most frequently seen in
dEDS (intracranial hemorrhage), cEDS (arterial dissections
and aneurysms), and kEDS (arterial dissections). No compli-
cations were reported yet in spEDS-B4GALT7, BCS, and
mEDS. Given the relatively high occurrence of vascular
complications in EDS patients, referral for cardiovascular
assessment and regular follow-up imaging may be required
upon diagnosis, especially for cEDS, dEDS, and kEDS. If
vascular complications are detected, the type and location of
a complication will guide treatment options. However, to
optimize management and care guidelines, future research
should be focused on more systematic documentation of
vascular and bleeding complications and their management
in natural history studies and registries.
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